Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells.
- Author:
Shi-Feng LU
1
;
Hua LU
;
Wen-Yi SHEN
;
Jian-Fu ZHANG
;
Peng LIU
;
Yong-Ren WANG
;
Li-Xia WANG
;
Hui YANG
;
Jian-Yong LI
Author Information
1. Department of Hematology, The First Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Boronic Acids;
pharmacology;
Bortezomib;
Humans;
Intercellular Adhesion Molecule-1;
metabolism;
K562 Cells;
NF-kappa B;
metabolism;
Protease Inhibitors;
pharmacology;
Pyrazines;
pharmacology
- From:
Journal of Experimental Hematology
2008;16(5):1006-1009
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the effects of proteasome inhibitor bortezomib (Velcade, PS-341) on the activation of NF-kappaB and the expression of intercellular adhesion molecule-1 (ICAM-1) in K562 cells. The K562 cells were incubated in the culture of RPMI 1640 with 10% calf serum in 12-well plates and exposed to 0, 10, 20, 30, 50 and 100 nmol/L of bortezomib for 6 hours. The activation of NF-kappaB was analyzed by SP immunohistochemistry, meanwhile RT-PCR was performed to detect expression of ICAM-1. The results showed that the activation of NF-kappaB and the expression of ICAM-1 in K562 cells decreased significantly after bortezomib treatment. The inhibitory effect on ICAM-1 was probably related with the activity suppression of NF-kappaB. It is concluded that proteasome inhibitor bortezomib downregulates the expression of K562 cell ICAM-1 by inhibiting the activity of NF-kappaB, which provides a new way for the target therapy in acute leukemia.
